Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.
about
Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case reportDevelopment of Novel Immunotherapies for Multiple MyelomaHow I treat plasma cell leukemia.Identification of novel pathogenic copy number aberrations in multiple myeloma: the Malaysian contextCombining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.Retrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma.Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocationsMonoclonal gammopathies of undetermined significance: a review.Interpreting the molecular biology and clinical behavior of multiple myeloma in the context of global gene expression profiling.Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.Many and multiple myeloma(s).Clinical, immunophenotypic, and genetic characterization of small lymphocyte-like plasma cell myeloma: a potential mimic of mature B-cell lymphomaClinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy.Heterogeneity in the multiple myeloma tumor clone.Genetic markers used for risk stratification in multiple myeloma.Genetic heterogeneity in multiple myeloma.Translocation t(11;14) (q13;q32) and genomic imbalances in multi-ethnic multiple myeloma patients: a Malaysian study.Genetic events in the pathogenesis of multiple myeloma.Clinical implications of chromosomal abnormalities in multiple myeloma.Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma.Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approachMolecular genetic analysis of haematological malignancies II: Mature lymphoid neoplasms.Review of molecular diagnostics in multiple myeloma.Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.Anti-CD20 monoclonal antibody therapy in multiple myeloma.Target fluorescence in-situ hybridization (Target FISH) for plasma cell enrichment in myeloma.Genomics in multiple myeloma.MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma.Plasma cell leukemia with t(11;14)(q13;q32) simulating lymphoplasmacytic lymphoma - a diagnostic challenge solved by flow cytometry.The Evolution of Prognostic Factors in Multiple Myeloma.Clinical impact of chromosomal aberrations in multiple myeloma.Lymphoplasmacytic lymphoma and other non-marginal zone lymphomas with plasmacytic differentiation.Genomic instability in multiple myeloma: mechanisms and therapeutic implications.Biclonal IgD and IgM Plasma Cell Myeloma: A Report of Two Cases and a Literature Review.The potential role of PD0332991 (Palbociclib) in the treatment of multiple myeloma.Cytogenetic Alterations in Multiple Myeloma: Prognostic Significance and the Choice of Frontline Therapy.
P2860
Q21198810-D27CCC09-F6DD-433E-8F11-706118E38B2CQ28066890-C4AE0E00-72A5-4091-8C90-681B172E85A9Q33402555-606B3CBE-26F9-4B3B-BA68-8767F494C5E0Q33614522-C06D2604-02FD-4E36-8022-79186EAF27B9Q33952805-B7076ACA-BF3E-49CC-B67F-7CF34291BAA1Q33956990-4B5C990A-C529-4D27-B15F-9ABFF9529578Q34115051-8B8EC692-A75B-4A79-BE09-1F194156FBAFQ34241661-BC1E6244-0FA7-4F91-B543-C542A8983D30Q34993904-5F51F31D-5290-46EE-8533-D77EEB8E9627Q35081172-E726E773-9FBD-42F4-8DF8-61F2463B1394Q35170927-7BA8BDCF-AE2A-4F1A-B6AA-F649E24F3849Q35170930-7EBEA04D-9301-44E5-8EE4-158A14100BD4Q35265979-9F7121CF-3887-4A01-B8FA-1E2DFB073B0EQ35545068-63C6FD65-3512-48C8-B9C5-9AF40C41AE6EQ35610245-0AE13ECB-25F4-4268-89B9-32265B2387F4Q35848356-EE34A718-55D9-4E83-87F2-0FEC3B302E79Q35854779-64A44A78-480B-4E7E-B03E-A4FBF328A802Q35910262-D48FBEE1-964D-4CEB-B400-DE6EEDF79A64Q35945858-B9AD5FB0-322A-4B03-8481-8F242E5D591EQ36331764-3080AA3B-CAB0-4DF0-A20C-742EA825F73AQ36380235-9C6BDA2A-15EC-4FC8-BB8D-8C8A19EBB21FQ36497416-48B198D8-54F8-40FA-A8C6-5F2F577C59F1Q36595290-3F6F47ED-D1BB-45CD-A553-EA558D5BE89BQ36754816-C256B09F-A15D-4364-8930-FDEA515653D8Q36779423-F1AA00CE-EAA4-4EB1-A6A1-4C8536F497CAQ36872779-77203EDD-17B9-4443-94F9-1BC3CC40E4C6Q36874362-B035C5BC-F4C2-4D57-9293-3DF3689750DCQ37037265-A63E7648-E707-4120-9FF7-EA5B7BB9A77BQ37101674-006730CA-2D9E-429E-AD36-6DEB18D5DA6BQ37178643-459C1B3A-4B72-4EE5-B16D-22D1E4786F00Q37197359-C6022CEC-F620-4D99-82C1-F923849560A9Q37262390-7D6882A0-F2D3-4CAC-8257-580F0632E6ABQ37683315-7A5358E6-FBAD-447B-B850-F4E46B0721E1Q37683483-AF049062-C0DE-44FC-9631-E3B61C72E4CCQ37821077-6D9A3900-2EAE-4782-A9A2-6A9EB7418452Q37901235-FE5DF83E-2EF4-46C4-B084-1EA9424917F8Q38115576-1C6EC613-6970-478D-8097-AE15A338A59CQ38172178-651F100F-1D8F-4991-BBEA-5B41B829B690Q38286180-BA45DEB8-0813-4BA1-8888-EDC377B8E4BDQ38617375-0D445488-9172-4E89-B60F-70CDDCFF8F86
P2860
Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Myeloma and the t
@nl
Myeloma and the t(11;14)(q13;q ...... ned unique subset of patients.
@en
type
label
Myeloma and the t
@nl
Myeloma and the t(11;14)(q13;q ...... ned unique subset of patients.
@en
prefLabel
Myeloma and the t
@nl
Myeloma and the t(11;14)(q13;q ...... ned unique subset of patients.
@en
P2093
P1433
P1476
Myeloma and the t(11;14)(q13;q ...... ned unique subset of patients.
@en
P2093
Brian Van Ness
David Harrington
Emily A Blood
Gordon W Dewald
James D Hoyer
Kimberly J Henderson
Martin M Oken
Neil E Kay
Philip R Greipp
Richard J Bailey
P304
P356
10.1182/BLOOD.V99.10.3735
P407
P577
2002-05-01T00:00:00Z